SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharma gets US FDA nod for Sanfoi’s DDAVP Nasal Spray Generic

26 Dec 2013 Evaluate

Sun Pharmaceutical Industries has received US Food and Drug Administration (US FDA) approval for Sanfoi’s DDAVP nasal Spray Generic, which is indicated as antidiuretic replacement therapy in the management of central cranial diabetes insipidus and for management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region.

The use of DDAVP Nasal Spray in patients with an established diagnosis will result in a reduction in urinary output with increase in urine osmolality and a decrease in plasma osmolality.

Recently, the company’s subsidiary granted the USFDA final approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Cymbalta, Duloxetine Delayed-Release Capsules USP, 20 mg, 30 mg and 60 mg. Duloxetine Delayed-Release Capsules USP, 20 mg, 30 mg and 60 mg are therapeutic equivalents of Eli Lilly & Company’s Cymbalta Delayed-Release Capsules.

Sun Pharmaceutical Industries is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.

 

Sun Pharma Inds. Share Price

1670.60 2.60 (0.16%)
21-Apr-2026 13:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1670.60
Dr. Reddys Lab 1220.90
Cipla 1231.05
Zydus Lifesciences 927.40
Lupin 2324.30
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×